DDInter150 DDInter1959
Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection. Azathiprine was granted FDA approval on 20 March 1968.
Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival. BTK is an enzyme that plays a role in oncogenic signalling pathways, promoting the survival and proliferation of malignant B cells. Compared to the first-generation BTK inhibitor [ibrutinib], zanubrutinib displays higher potency and selectivity for BTK with fewer off-target effects. Due to this enhanced selectivity towards BTK, zanubrutinib belongs to the second-generation BTK inhibitor drug group that also includes [acalabrutinib], which was approved by the FDA in 2017. Zanubrutinib was granted accelerated approval by the FDA in November 2019 based on clinical trial results that demonstrated an 84% overall response rate from zanubrutinib therapy in patients with MCL, which measures the proportion of patients in a trial whose tumour is entirely or partially destroyed by a drug. It is currently marketed under the trade name BRUKINSA™ and is available as oral capsules. In August 2021, the FDA granted accelerated approval to zanubrutinib for the treatment of adults with Waldenström’s macroglobulinemia. This indication is valid in the US, Europe, and Canada. In September 2021, zanubrutinib was granted another accelerated approval for the treatment of relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen. In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended zanubrutinib be granted marketing authorization for the treatment of chronic lymphocytic leukemia.
Azathioprine {u} (Compound) upregulates {v} (Gene) COL11A1
COL11A1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zanubrutinib
Azathioprine {u} (Compound) upregulates {v} (Gene) PCK2
PCK2 {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Dasatinib {u} may lead to a major life threatening interaction when taken with {v} Zanubrutinib
Azathioprine {u} (Compound) downregulates {v} (Gene) RPS4Y1
RPS4Y1 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zanubrutinib
Azathioprine {u} (Compound) downregulates {v} (Gene) CYCS
CYCS {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Crizotinib {u} may lead to a major life threatening interaction when taken with {v} Zanubrutinib
Azathioprine {u} (Compound) causes {v} (Side Effect) Uveitis
Uveitis {u} (Side Effect) is caused by {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zanubrutinib
Azathioprine {u} (Compound) causes {v} (Side Effect) Uveitis
Uveitis {u} (Side Effect) is caused by {v} (Compound) Dabrafenib
Dabrafenib {u} may lead to a major life threatening interaction when taken with {v} Zanubrutinib
Azathioprine {u} (Compound) treats {v} (Disease) systemic lupus erythematosus
systemic lupus erythematosus {u} (Disease) is treated by {v} (Compound) Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Zanubrutinib
Azathioprine {u} (Compound) treats {v} (Disease) systemic lupus erythematosus
systemic lupus erythematosus {u} (Disease) is palliated by {v} (Compound) Acetylsalicylic acid
Acetylsalicylic acid {u} may lead to a major life threatening interaction when taken with {v} Zanubrutinib
Azathioprine {u} (Compound) binds {v} (Gene) HPRT1
HPRT1 {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Ponatinib {u} may lead to a major life threatening interaction when taken with {v} Zanubrutinib
Azathioprine {u} (Compound) binds {v} (Gene) TPMT
TPMT {u} (Gene) is upregulated by {v} (Compound) Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zanubrutinib
Azathioprine (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Azathioprine (Compound) upregulates PCK2 (Gene) and PCK2 (Gene) is upregulated by Dasatinib (Compound) and Dasatinib may lead to a major life threatening interaction when taken with Zanubrutinib
Azathioprine (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Azathioprine (Compound) downregulates CYCS (Gene) and CYCS (Gene) is downregulated by Crizotinib (Compound) and Crizotinib may lead to a major life threatening interaction when taken with Zanubrutinib
Azathioprine (Compound) causes Uveitis (Side Effect) and Uveitis (Side Effect) is caused by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Azathioprine (Compound) causes Uveitis (Side Effect) and Uveitis (Side Effect) is caused by Dabrafenib (Compound) and Dabrafenib may lead to a major life threatening interaction when taken with Zanubrutinib
Azathioprine (Compound) treats systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is treated by Leflunomide (Compound) and Leflunomide may lead to a major life threatening interaction when taken with Zanubrutinib
Azathioprine (Compound) treats systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is palliated by Acetylsalicylic acid (Compound) and Acetylsalicylic acid may lead to a major life threatening interaction when taken with Zanubrutinib
Azathioprine (Compound) binds HPRT1 (Gene) and HPRT1 (Gene) is downregulated by Ponatinib (Compound) and Ponatinib may lead to a major life threatening interaction when taken with Zanubrutinib
Azathioprine (Compound) binds TPMT (Gene) and TPMT (Gene) is upregulated by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib